{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T22:08:17Z","timestamp":1707516497006},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2006,6,1]]},"DOI":"10.1532\/ijh97.05180","type":"journal-article","created":{"date-parts":[[2006,6,21]],"date-time":"2006-06-21T20:31:27Z","timestamp":1150921887000},"page":"433-438","source":"Crossref","is-referenced-by-count":15,"title":["Molecular Analysis of Chronic Eosinophilic Leukemia with t(4;10) Showing Good Response to Imatinib Mesylate"],"prefix":"10.1007","volume":"83","author":[{"given":"Haruko","family":"Tashiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Shirasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuho","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritaka","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kawasugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shirafuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. <i>Br J Haematol.<\/i> 2003;<b>122<\/b>:173-179.","DOI":"10.1046\/j.1365-2141.2003.04458.x"},{"key":"E00002","doi-asserted-by":"crossref","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Nat Med. 1996;<b>2<\/b>:561-566.","DOI":"10.1038\/nm0596-561"},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med. 2001;<b>344<\/b>:1031-1037.","DOI":"10.1056\/NEJM200104053441401"},{"key":"E00004","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.N Engl J Med. 2002;<b>346<\/b>:645-652.","DOI":"10.1056\/NEJMoa011573"},{"key":"E00005","doi-asserted-by":"crossref","unstructured":"Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.Blood. 2002;<b>99<\/b>:3530-3539.","DOI":"10.1182\/blood.V99.10.3530"},{"key":"E00006","doi-asserted-by":"crossref","unstructured":"Druker BJ. Imatinib as a paradigm of targeted therapies.Adv. Cancer Res. 2004;<b>91<\/b>:1-30.","DOI":"10.1016\/S0065-230X(04)91001-9"},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate.Lancet. 2002;<b>359<\/b>:1577-1578.","DOI":"10.1016\/S0140-6736(02)08505-7"},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.Blood. 2003;<b>101<\/b>:3391-3397.","DOI":"10.1182\/blood-2002-10-3103"},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.Blood. 2003;<b>101<\/b>:4714-4716.","DOI":"10.1182\/blood-2003-01-0081"},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.Blood. 2003;<b>101<\/b>:4660-4666.","DOI":"10.1182\/blood-2003-01-0006"},{"key":"E00011","doi-asserted-by":"crossref","unstructured":"Imashuku S, Kakazu N, Ueda I, et al. Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations.Int J Hematol. 2005;<b>81<\/b>:310-314.","DOI":"10.1532\/IJH97.04185"},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.N Engl J Med. 2003;<b>348<\/b>:1201-1214.","DOI":"10.1056\/NEJMoa025217"},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.Medicine (Baltimore). 1975;<b>54<\/b>:1-27.","DOI":"10.1097\/00005792-197501000-00001"},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Bentley HP Jr, Reardon AE, Knoedler JP, et al. Eosinophilic leukemia: report of a case, with review and classification. Am J Med. 1961;<b>30<\/b>:310-322.","DOI":"10.1016\/0002-9343(61)90102-4"},{"key":"E00015","unstructured":"Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds.World Health Organization of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 29-31."},{"key":"E00016","doi-asserted-by":"crossref","unstructured":"Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor \u03b2 to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. <i>Cell.<\/i> 1994;<b>77<\/b>:307-316.","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Coutre S, Gotlib J. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.Semin Cancer Biol. 2004;<b>14<\/b>:307-315.","DOI":"10.1016\/j.semcancer.2004.03.002"},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome.Blood. 1994;<b>83<\/b>:2759-2779.","DOI":"10.1182\/blood.V83.10.2759.2759"},{"key":"E00019","doi-asserted-by":"crossref","unstructured":"Muller AM, Martens UM, Hofmann SC, Bruckner-Tuderman L, Mertelsmann R, Lubbert M. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. <i>Ann Hematol.<\/i> 2006;<b>85<\/b>:1-16.","DOI":"10.1007\/s00277-005-1084-7"},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Heizer WD, Peterson JL. Acute myeloblastic leukemia following prolonged treatment of Crohn's disease with 6-mercaptopurine.Dig Dis Sci. 1998;<b>43<\/b>:1791-1793.","DOI":"10.1023\/A:1018896006155"},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"Super HJ, McCabe NR, Thirman MJ, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.Blood. 1993;<b>82<\/b>:3705-3711.","DOI":"10.1182\/blood.V82.12.3705.bloodjournal82123705"},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.Proc Natl Acad Sci USA. 2002;<b>99<\/b>:10700-10705.","DOI":"10.1073\/pnas.162140299"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFR\u03b1 fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.Blood. 2004;<b>103<\/b>:2879-2891.","DOI":"10.1182\/blood-2003-06-1824"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR\u03b2 and FIP1L1-PDGFR\u03b1 in vitro and in vivo.Blood. 2005;<b>106<\/b>:3206-3213.","DOI":"10.1182\/blood-2005-05-1932"}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.05180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T20:11:57Z","timestamp":1683490317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.05180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,6,1]]}},"alternative-id":["D2728K8122613247"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.05180","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}